(MedPage Today) — CHICAGO — Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant non-small cell lung cancer…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115877
Author :
Publish date : 2025-06-03 17:29:00
Copyright for syndicated content belongs to the linked Source.
